CD274 and neoplasm: All the subgroup analyses (including PD-L1 and LAG-3 expression, BRAF mutation status, M1c stage, higher tumor burden, higher LDH, etc.)favored Relatlimab–Nivolumab over Nivolumab, and ORR were higher in patients with LAG-3 ≥ 1% and PD-L1 ≥ 1%.